Modulation of Antibody Responses by Conjugates of Antigens with Monomethoxypolyethylene Glycol
摘要:
The possibility of selectively downregulating the host's immune response to a given antigen represents one of the most formidable challenges of modern immunology in relation to the development of new therapies for IgE-mediated allergies, autoimmune diseases, and the prevention of immune rejection of organ transplants. Similar considerations apply to an increasing number of promising therapeutic modalities for a broad spectrum of diseases, which would involve the use of foreign biologically active agents potentially capable of modulating the immune response, provided they were not also immunogenic. Among these agents, one may cite (1) xenogeneic monoclonal or polyclonal antibodies (collectively referred to here as xIg) against different epitopes of the patients' CD4 + cells, 1,2 administered alone or in combination with immunosuppressive drugs for treatment of rheumatoid arthritis and other autoimmune diseases, or for the suppression of graft versus host reactions and of the immune rejection of organ transplants, 1,2 and (2) "magic bullets" for the destruction of tumor cells, 3–5 which consist of anti-tumor xIg to which are coupled toxins (Tx), or radionuclides, or chemotherapeutic drugs. However, in most cases the patients produce antibodies to the injected xIg and to the even more immunogenic immunotoxins (xIg-Tx); consequently, the therapeutic effectiveness of these immunological strategies is undermined by the patients' antibodies which prevent these "bullets" from reaching their target cells. In addition, the repeated administration of these agents may result in serious complications, namely, serum sickness, anaphylactic symptoms (i.e., bronchospasm, dyspnea, and hypotension), and/or the deposition in the liver of toxic immune complexes leading frequently to hepatotoxicity. 6,7 Similar limitations apply to the use of hormones or other regulatory factors, such as lymphokines and growth factors, synthesized by recombinant DNA technology, which are often immunogenic 8 probably because of small differences in their conformational characteristics or in their glycosidic constituents in relation to their natural, human counterparts.
展开
关键词:
Therapeutic protein Xenogenic monoclonal antibody Lymphokine Immunogenicity Immunotoxin Immunotherapy Immunotargeting Tolerogenic monomethoxypoly(ethylene glycol) conjugate AIDS Graft-versus-host disease
DOI:
10.1007/978-1-4899-0703-5_10
被引量:
年份:
1989
通过文献互助平台发起求助,成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
来源期刊
引用走势
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用!